Document:

Caleco Pharma Corp: Exhibit 10.3 - Filed by newsfilecorp.com

	AMENDMENT AGREEMENT TO SHARE PURCHASE
      AGREEMENT 
	 
	THIS AGREEMENT is dated the 19th day of
      March, 2010. 
	 
	BETWEEN: 
		NATAC BIOTECH, S.L., a Spanish
      corporation having an address at Calle Ana de Austria, 28660 Boadilla del
      Monte, Madrid, Spain 	
	 	 	 
	 	(hereinafter called "Natac") 	 
	OF THE FIRST PART 
	AND: 
		ANTONIO DELGADO ROMERO, an
      individual having an address at Calle Manuel de Falla 4a, 05260 Avila,
      Spain. 	
	 
	 	(hereinafter called "Romero") 	 
	OF THE SECOND PART  
	AND:
		JOSE CARLOS QUINTELA FERNANDEZ,
      an individual having an address at Calle Tellez 28007,
      Madrid, Spain. 	
	 	(hereinafter called "Fernandez") 	 
	OF THE THIRD
    PART 
	AND:
		CALECO PHARMA CORP., a Nevada
      corporation having an address at Suite 410 – 103 East Holly Street,
      National Bank Building, Bellingham, WA 98225. 	
	 
	 	(hereinafter called "Caleco") 	 
	OF THE FOURTH PART  

WHEREAS:

A.          Under
the terms of a Share Purchase Agreement (the “Share Purchase Agreement”) dated
February 10, 2010 among Natac, Caleco, Romero and Fernandez, (together, the
“Vendors”), Caleco agreed to purchase from the Vendors an aggregate of 36 shares
of the capital stock of Natac held by the Vendors (the “Natac Shares”). In
consideration of the Natac Shares, Caleco agreed to issue an aggregate of
4,300,000 shares of its common stock to the Vendors on closing of the Share
Purchase Agreement;

B.          Under
the terms of the Share Purchase Agreement, the parties agreed to close the
acquisition of the Natac Shares on March 19, 2010 (the “Closing Date”); and

C.          Natac
and the Vendors have agreed to extend the Closing Date to April 19, 2010 in
accordance with the terms of this Agreement.

NOW, THEREFORE, in consideration of the premises
contained herein and the sum of $10.00 paid by Caleco to Natac, the receipt and
sufficiency are hereby acknowledged, Natac and Caleco agree as follows:

	1. 	Definitions. Except as
      otherwise set out herein, capitalized terms used in this Agreement shall
      have 
	  	the same meaning as specified in the
      Share Purchase Agreement. 
	  	  	  
	2. 	Amendment. Section 7.1 of the
      Share Purchase Agreement is replaced in its entirety with the 
	  	following: 
	  	  	  
		“7.1 The closing of this Agreement
      shall occur on a date, time and place as mutually agreed to by the
      parties, but in any event no later than April 19, 2010 (the “Closing
      Date”).” 

	3. 	
      No Other Modification. The parties confirm that
      the terms, covenants and conditions of the Share Purchase Agreement remain
      unchanged and in full force and effect, except as modified by this
      Agreement.

	 	 
	4. 	
      Independent Legal Advice. This Agreement has been
      prepared by O’Neill Law Group PLLC acting solely on behalf of Caleco, and
      Natac and the Vendors acknowledge that they have been advised to obtain
      independent legal advice.

	 	 
	5. 	
      Successors and Assigns. Except as otherwise
      expressly provided herein, the provisions hereof shall inure to the
      benefit of, and be binding upon, the successors, assigns, heirs, executors
      and administrators of the parties hereto.

	 	 
	6. 	
      Entire Agreement. This Agreement constitutes the
      full and entire understanding and agreement between the parties with
      regard to the subject hereof.

	 	 
	7. 	
      Counterparts. This Agreement may be executed in
      two or more counterparts, each of which shall constitute an original, but
      all of which, when taken together, shall constitute but one instrument,
      and shall become effective when one or more counterparts have been signed
      by each party hereto and delivered to the other
parties.

IN WITNESS WHEREOF, the parties have duly executed and
delivered this Agreement as of the date first written above.

	NATAC BIOTECH S.L. 	 	  
	  	 	  
	  	 	  
	  /s/
      Lourdes Marquez	 	  
	By Its Authorized Signatory 	 	  
	  	 	  
	SIGNED, SEALED AND DELIVERED 	 	  
	BY ANTONIO DELGADO ROMERO 	 	  
	in the presence of: 	 	  
	  	 	  
	  
      /s/ Jose Carlos Quintela Fernandez	 	/s/
      Antonio Delgado Romero
	Signature of Witness 	 	ANTONIO DELGADO ROMERO 
	  	 	  
	Jose Carlos Quintela Fernandez 	 	  
	Name 	 	  
	  	 	  
	SIGNED, SEALED AND DELIVERED 	 	  
	BY JOSE CARLOS QUINTELA FERNANDEZ 	 	  
	in the presence of: 	 	  
	  	 	  
	  /s/
      Antonio Delgado Romero	 	/s/
      Jose Carlos Quintela Fernandez
	Signature of Witness 	 	JOSE CARLOS QUINTELA FERNANDEZ 
	  	 	  
	Antonio Delgado
      Romero 	 	  
	Name 	 	  
	  	 	  
	CALECO PHARMA CORP. 	 	  
	  	 	  
	  	 	  
	 /s/ John
      Boschert	 	  
	By Its Authorized Signatory 	 	  

2Caleco Pharma Corp: Exhibit 10.4 - Filed by newsfilecorp.com

	AMENDMENT AGREEMENT TO LAB FACILITIES AND
      SERVICES AGREEMENT 
	 
	THIS AGREEMENT is dated the 19th
      day of March, 2010. 
	 	 	 
	 BETWEEN: 
		NATAC BIOTECH, S.L., a Spanish
      corporation having an address at Calle Ana de Austria, 28660 Boadilla del
      Monte, Madrid, Spain 	
	 
	 	(hereinafter called "Natac") 	 
	OF THE FIRST
    PART  
	 AND: 		 
		CALECO PHARMA CORP., a Nevada
      corporation having an address at Suite 410 – 103 East Holly Street,
      National Bank Building, Bellingham, WA 98225. 	
	 
	 	(hereinafter called "Caleco") 	 
	OF THE SECOND PART  

WHEREAS:

A.          
Natac and Caleco entered into a Lab Facilities and Services Agreement (the “Lab
Facilities and Services Agreement”) dated February 18, 2010 pursuant to which
Natac has agreed to grant access to its laboratory facility and procure certain
laboratory services to Caleco in accordance with the terms and conditions of the
Lab Facilities and Services Agreement.

B.          Under
the terms of the Lab Facilities and Services Agreement, Caleco and Natac agreed
to close the Lab Facilities and Services Agreement on March 19, 2010 (the
“Closing Date”).

C.          Natac
has agreed to extend the Closing Date to April 19, 2010 and extend all payment
dates and the term of the Lab Facilities and Services Agreement by an additional
thirty (30) days.

NOW, THEREFORE, in consideration of the premises
contained herein and the sum of $10.00 paid by Caleco to Natac, the receipt and
sufficiency are hereby acknowledged, Natac and Caleco agree as follows:

	1. 	
      Definitions. Except as otherwise set out herein,
      capitalized terms used in this Agreement shall have the same meaning as
      specified in the Lab Facilities and Services Agreement.

	 	 
	2. 	
      Amendment. The Lab Facilities and Services
      Agreement be amended as follows:

	 	(i) 	
      Section 2.2(b) of the Lab Facilities and Services
      Agreement is replaced in its entirety with the following:

	 	 	 
	 		 “(b)	
      issuance of a promissory note in the amount of 130,000
      Euros payable on or before April 19, 2010 (the “Closing Date”) (which
      promissory note has been issued on February 10, 2010)”

	 	 	 	 
	 	(ii) 	
      Section 2.2(c) of the Lab Facilities and Services
      Agreement is replaced in its entirety with the following:

	 	 	 
	 		 “(c)	
      100,000 Euros on or before April 30, 2010, July 31, 2010,
      October 31, 2010 and January 31, 2011; and”

	 	 	 	 
	 	(iii) 	
      Section 2.2(d) of the Lab Facilities and Services
      Agreement is replaced in its entirety with the
following:

	 		 “(d)	
      125,000 Euros on or before:

	 	 	 	 	 
	 		 	(i)	
      April 30, 2011, July 31, 2011, October 31, 2011 and
      January 31, 2012; and

	 	 	 	 	 
	 		 	(ii)	
      April 30, 2012, July 31, 2012, October 31, 2012 and
      January 31, 2013.”

	 	 	 	 	 
	 	(iv) 	
      Section 5.1 of the Lab Facilities and Services Agreement
      is replaced in its entirety with the following:

	 	 	 	 	 
	 		 “5.1	
      The term of this Agreement shall commence on April 19,
      2010 (the “Closing Date”) and continue until April 30, 2013 (the
      “Term”)”

	3. 	
      Extension of Promissory Note. Natac agrees to
      extend the due date of the promissory note dated February 10, 2010 in the
      amount of 130,000 Euros to April 19, 2010.

	 	 
	4. 	
      No Other Modification. The parties confirm that
      the terms, covenants and conditions of the Lab Facilities and Services
      Agreement remain unchanged and in full force and effect, except as
      modified by this Agreement.

	 	 
	5. 	
      Independent Legal Advice. This Agreement has been
      prepared by O’Neill Law Group PLLC acting solely on behalf of Caleco, and
      Natac acknowledges that it has been advised to obtain independent legal
      advice.

	 	 
	6. 	
      Successors and Assigns. Except as otherwise
      expressly provided herein, the provisions hereof shall inure to the
      benefit of, and be binding upon, the successors, assigns, heirs, executors
      and administrators of the parties hereto.

	 	 
	7. 	
      Entire Agreement. This Agreement constitutes the
      full and entire understanding and agreement between the parties with
      regard to the subject hereof.

	 	 
	8. 	
      Counterparts. This Agreement may be executed in
      two or more counterparts, each of which shall constitute an original, but
      all of which, when taken together, shall constitute but one instrument,
      and shall become effective when one or more counterparts have been signed
      by each party hereto and delivered to the other
parties.

IN WITNESS WHEREOF, the parties have duly executed and
delivered this Agreement as of the date first written above.

NATAC BIOTECH S.L.

/s/ Lourdes
Marquez                                       
 
By Its Authorized Signatory

CALECO PHARMA CORP.

/s/ John
Boschert                                            

By Its Authorized Signatory

2ex4a.htm

ARTICLES OF INCORPORATION

OF

SUBPRIME ADVANTAGE, INC.

KNOW ALL MEN BY THESE PRESENTS:

 

That the undersigned, being at least eighteen (18) years of age and acting as the incorporator of the Corporation hereby being formed under and pursuant to the laws of the State of Nevada, does hereby certify that:

 

Article I - NAME

 

The exact name of this corporation is:  SUBPRIME ADVANTAGE, INC.

 

Article II - REGISTERED OFFICE AND RESIDENT AGENT

 

The registered office and place of business in the State of Nevada of this corporation shall be located at 9850 S. Maryland Pkwy, Suite 197, Las Vegas, NV 89183.  The resident agent of the corporation is SLI, whose address is 9850 S. Maryland Pkwy, Suite 197, Las Vegas, NV 89183.

 

Article III - DURATION

 

The Corporation shall have perpetual existence.

 

Article IV - PURPOSES

 

The purpose, object and nature of the business for which this corporation is organized are:

 

(a)  To engage in any lawful activity, (b) To carry on such business as may be necessary, convenient, or desirable to accomplish the above purposes, and to do all other things incidental thereto which are not forbidden by law or by these Articles of Incorporation.

 

Article V - POWERS

 

This Corporation is formed pursuant to Chapter 78 of the Nevada Revised Statutes.  The powers of the Corporation shall be those powers granted by 78.060 and 78.070 of the Nevada Revised Statutes under which this corporation is formed.  In addition, the corporation shall have the following specific powers:

 

(a)  To elect or appoint officers and agents of the corporation and to fix their compensation; (b)  To act as an agent for any individual, association, partnership, corpora­tion or other legal entity; (c)  To receive, acquire, hold, exercise rights arising out of the ownership or possession thereof, sell,
or otherwise dispose of, shares or other interests in, or obligations of, individuals, association, partnerships, corporations, or governments; (d)  To receive, acquire, hold, pledge, transfer, or otherwise dispose of shares of the corporation, but such shares may only be purchased, directly or indirectly, out of earned surplus;  (e)  To make gifts or contributions for the public welfare or for charitable, scientific or educational purposes.

 

Article VI - CAPITAL STOCK

 

Section 1.  Authorized Shares.  The total number of shares which this corporation is authorized to issue is 100,000,000 shares of Common Stock of $.001 par value. The authority of the Corporation to issue non-voting convertible and/or non-voting non-convertible
preferred shares together with additional classes of shares may be limited by resolution of the Board of Directors of the Corporation.

 

Section 2.  Voting Rights of Stockholders.  Each holder of the Common Stock shall be entitled to one vote for each share of stock standing in his name on the books of the corporation.

 

Section 3.  Consideration for Shares.  The Common Stock shall be issued for such consideration, as shall be fixed from time to time by the Board of Directors.  In the absence of fraud, the judgment of the Directors as to the value of any property
or services received in full or partial payment for shares shall be conclusive.  When shares are issued upon payment of the consideration fixed by the Board of Directors, such shares shall be taken to be fully paid stock and shall be non-assessable.  The Articles shall not be amended in this particular.

 

Section 4.  Stock Rights and Options.  The corporation shall have the power to create and issue rights, warrants, or options entitling the holders thereof to purchase from the corporation any shares of its capital stock of any class or classes, upon such
terms and conditions and at such times and prices as the Board of Directors may provide, which terms and conditions shall be incor­porated in an instrument or instruments evidencing such rights.  In the absence of fraud, the judgment of the Directors as to the adequacy of consideration for the issuance of such rights or options and the sufficiency thereof shall be conclusive.

 

Article VII - MANAGEMENT

 

For the management of the business, and for the conduct of the affairs of the corporation, and for the future definition, limitation, and regulation of the powers of the corporation and its directors and stockholders, it is further provided:

 

Section 1.  Size of Board.  The initial number of the Board of Directors shall be one (1).  Thereafter, the number of directors shall be as specified in the Bylaws of the corporation, and such number may from time to time be increased or decreased
in such manner as prescribed by the Bylaws.  Directors need not be stockholders.

 

Section 2.  Powers of Board.  In furtherance and not in limitation of the powers conferred by the laws of the State of Nevada, the Board of Directors is expressly authorized and empowered:

 

(a)  To make, alter, amend, and repeal the Bylaws subject to the power of the stockholders to alter or repeal the Bylaws made by the Board of Directors;

 

(b)  Subject to the applicable provisions of the Bylaws then in effect, to determine, from time to time, whether and to what extent, and at what times and places, and under what conditions and regulations, the accounts and books of the corporation, or any of them, shall be open to stockholder inspection.  No stockholder
shall have any right to inspect any of the accounts, books or documents of the corporation, except as permitted by law, unless and until authorized to do so by resolution of the Board of Directors or of the stockholders of the Corporation;

 

(c)  To authorize and issue, without stockholder consent, obligations of the Corporation, secured and unsecured, under such terms and conditions as the Board, in its sole discretion, may determine, and to pledge or mortgage, as security therefore, any real or personal property of the corporation, including after-acquired property;

 

(d)  To determine whether any and, if so, what part of the earned surplus of the corporation shall be paid in dividends to the stockholders, and to direct and determine other use and disposition of any such earned surplus;

 

(e)  To fix, from time to time, the amount of the profits of the corporation to be reserved as working capital or for any other lawful purpose;

 

(f)  To establish bonus, profit-sharing, stock option, or other types of incentive compensation plans for the employees, including officers and directors, of the corporation, and to fix the amount of profits to be shared or distributed, and to determine the persons to participate in any such plans and the amount of their respective
participations.

 

(g)  To designate, by resolution or resolutions passed by a majority of the whole Board, one or more committees, each consisting of two or more directors, which, to the extent permitted by law and authorized by the resolution or the Bylaws, shall have and may exercise the powers of the Board;

 

(h)  To provide for the reasonable compensation of its own members by Bylaw, and to fix the terms and conditions upon which such compensation will be paid;

 

(i)  In addition to the powers and authority hereinbefore, or by statute, expressly conferred upon it, the Board of Directors may exercise all such powers and do all such acts and things as may be exercised or done by the corporation, subject, nevertheless, to the provisions of the laws of the State of Nevada, of these Articles
of Incorporation, and of the Bylaws of the corporation.

 

Section 3.  Interested Directors.  No contract or transac­tion between this corporation and any of its directors, or between this corporation and any other corporation, firm, association, or other legal entity shall be invalidated by reason of the
fact that the director of the corporation has a direct or indirect interest, pecuniary or otherwise, in such corporation, firm, association, or legal entity, or because the interested director was present at the meeting of the Board of Directors which acted upon or in reference to such contract or transaction, or because he participated in such action, provided that:  (1)  the interest of each such director shall have been disclosed to or known by the Board and a disinterested majority of
the Board shall have, nonetheless, ratified and approved such contract or transaction (such interested director or directors may be counted in determining whether a quorum is present for the meeting at which such ratification or approval is given); or (2) the conditions of N.R.S. 78.140 are met.

 

Section 4.  Name and Address.  The name and post office address of the first Board of Directors which shall consist of one (1) person who shall hold office until his successors are duly elected and qualified, are as follows:

 

NAME                                                          
  ADDRESS

       Molly Country                                                      501
W. Broadway

Suite A-323

San Diego, CA 92101

Article VIII - PLACE OF MEETING; CORPORATE BOOKS

 

Subject to the laws of the State of Nevada, the stockholders and the directors shall have power to hold their meetings, and the directors shall have power to have an office or offices and to maintain the books of the Corporation outside the State of Nevada, at such place or places as may from time to time be designated in the Bylaws or
by appropriate resolution.

 

Article IX - AMENDMENT OF ARTICLES

 

The provisions of these Articles of Incorporation may be amended, altered or repealed from time to time to the extent and in the manner prescribed by the laws of the State of Nevada, and additional provisions authorized by such laws as are then in force may be added.  All rights herein conferred on the directors, officers and
stockholders are granted subject to this reservation.

 

Article X - INCORPORATOR

 

The name and address of the incorporator signing these Articles of Incorporation are as follows:

 

NAME                                                      POST
OFFICE ADDRESS

     Molly Country                                                        501
W. Broadway

Suite A-323

San Diego, CA 92101

Article XI - LIMITED LIABILITY OF OFFICERS AND DIRECTORS

 

Except as hereinafter provided, the officers and directors of the corporation shall not be personally liable to the corporation or its stockholders for damages for breach of fiduciary duty as a director or officer.  This limitation on personal liability shall not apply to acts or omissions which involve intentional misconduct,
fraud, knowing violation of law, or unlawful distributions prohibited by Nevada Revised Statutes Section 78.300.

 

Article XII – TRANSACTIONS WITH STOCKHOLDERS

 

Section 1.                      CONTROL SHARE ACQUISITION EXEMPTION. The corporation elects not to be governed by the provisions of NRS.§78.378 to NRS.§78.3793
generally known as the “Control Share Acquisition Statute” under the Nevada Business Corporation Law, which contains a provision governing “Acquisition of Controlling Interest.”

 

Section 2.                      COMBINATIONS WITH INTERESTED STOCKHOLDERS. The corporation elects not to be governed by the provisions of NRS §78.411 through NRS §78.444, inclusive, of the Nevada Business Corporation
Law.

IN WITNESS WHEREOF, the undersigned incorporator has executed these Articles of Incorporation this 16th day of December, 2009.

/s/ Molly Country

                                                                        
Molly Country

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]